Efficacy News and Research

RSS

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of the 24-week treatment phase of the company's Phase 3 registration study of GATTEX® (teduglutide).

11 Jan 2011

LibiGel may be the first FDA approved product to treat HSDD in menopausal women

BioSante Pharmaceuticals, Inc., a pharmaceutical company developing products for the treatment of female sexual health, today announced results of a survey of over 100 Obstetrician/Gynecologists and Primary Care Physicians regarding the need for an FDA-approved drug to treat a form of Female Sexual Dysfunction (FSD) known as Hypoactive Sexual Desire Disorder (HSDD).

11 Jan 2011

Shionogi brings KAPVAY ADHD drug to the U.S market

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial availability for the non-central nervous system stimulant medication KAPVAY™, an extended-release oral formulation of clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.

10 Jan 2011

Neomend receives CE Mark for ProGEL PLATINUM Surgical Sealant

Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced it has received the European Union CE Mark for the company's ProGEL® PLATINUM Surgical Sealant.

10 Jan 2011

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Adolor Corporation today announced that it is initiating a second Phase 2 study of ADL5945 in chronic non-cancer pain patients suffering from opioid-induced constipation (OIC).

10 Jan 2011

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Sangamo BioSciences, Inc. announced today that the company completed enrollment of its Phase 2b double-blind, placebo-controlled clinical trial (SB-509-901) in subjects with diabetic neuropathy (DN). The company expects to have efficacy data from this study in the second half of 2011. The company also plans to present the first human clinical data from its Phase 1 trials of SB-728-T in HIV/AIDS in the first quarter of 2011.

10 Jan 2011

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Oncolytics Biotech Inc. announced today that a U.S. Phase I study of REOLYSIN® in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrollment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.

10 Jan 2011

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

Bioheart, Inc. announced positive efficacy data has been reported from the registry study of bone marrow and adipose derived stem cells for the treatment of end stage critical limb ischemia with wounds. Vaclav Prochazka MD, PhD, MSc., of University Hospital Ostrava, Czech Republic presented data at the American Academy of Anti-Aging Medicine Conference in Las Vegas last month.

10 Jan 2011

KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced the initiation of two European Phase III studies evaluating ATX-101, a first-in-class injectable adipolytic agent, for the reduction of localized fat under the chin (submental fat).

10 Jan 2011

Scientists discover new anti-cancer mechanism

Scientists attached to VIB and K.U.Leuven have succeeded in decoding a potential new anti-cancer mechanism. The researchers discovered that normalizing abnormal tumor blood vessels through HRG prevents metastasis of tumor cells and enhances chemotherapy efficiency.

10 Jan 2011

Anchor announces rapid progress in OMJPI collaboration for developing GPCR therapeutic compounds

Anchor Therapeutics today announced that it has successfully completed the first stage of its collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals.

10 Jan 2011

ADA commends HHS for reaffirming safety, efficacy of optimal community water fluoridation

The American Dental Association (ADA) today commended the Federal agencies responsible for public health and safety for recalibrating the ratio of fluoride to water that they consider optimal based on scientific evaluation and the full appreciation of fluoride received from all sources.

7 Jan 2011

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

Dendreon Corporation today announced several updates regarding the U.S. commercialization of PROVENGE® (sipuleucel-T), the European strategy for PROVENGE, and progress on its pipeline.

7 Jan 2011

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

BIND Biosciences announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. BIND-014, the first product candidate to enter clinical evaluation from BIND's broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.

7 Jan 2011

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

Pharmasset, Inc., announced today positive data from interim analyses of two of its clinical programs: the HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase 2b trial and the 14 day PSI-938 monotherapy cohort of the dual nucleotide study.

7 Jan 2011

ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.

7 Jan 2011

TD2 and Oncoholdings partner to accelerate development of superior oncology agents

TGen Drug Development (TD2) and Oncoholdings Inc. announced today a partnership agreement that could lead to the prompt development of new anti-cancer agents.

7 Jan 2011

Positive results from LifeCycle Pharma's LCP-Tacro comparative trial in de novo liver transplant patients

LifeCycle Pharma A/S has announced positive top-line results from a Phase 2 clinical trial involving 58 patients comparing LCP-Tacro™ tablets administered once-daily versus Prograf® (tacrolimus) capsules (Astellas Pharma) administered twice-daily in de novo liver transplant patients for one year.

7 Jan 2011

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.

7 Jan 2011

CeNeRx commences TriRima Phase II trial for treatment resistant depression

CeNeRx BioPharma, today reported that it has initiated a Phase II trial of its new formulation of TriRima, the company's novel antidepressant in development as monotherapy for treatment resistant depression.

7 Jan 2011

Efficacy News and Research

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

LibiGel may be the first FDA approved product to treat HSDD in menopausal women

Shionogi brings KAPVAY ADHD drug to the U.S market

Neomend receives CE Mark for ProGEL PLATINUM Surgical Sealant

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Bioheart reports positive data from adipose derived stem cells study in critical limb ischemia

KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat

Scientists discover new anti-cancer mechanism

Anchor announces rapid progress in OMJPI collaboration for developing GPCR therapeutic compounds

ADA commends HHS for reaffirming safety, efficacy of optimal community water fluoridation

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

TD2 and Oncoholdings partner to accelerate development of superior oncology agents

Positive results from LifeCycle Pharma's LCP-Tacro comparative trial in de novo liver transplant patients

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

CeNeRx commences TriRima Phase II trial for treatment resistant depression

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News